Login to Your Account

Ablynx, Eddingpharm Ink Chinese Pact on RANK Ligand Inhibitor

By Cormac Sheridan
Staff Writer

Wednesday, October 23, 2013

Ablynx NV continues to crank out deals, its latest being a regional accord with Chinese specialty pharma firm Eddingpharm Co. Ltd. to develop and commercialize its anti-RANKL nanobody ALX-0141, for which it is receiving €2 million (US$2.7 million) up front, plus commercial milestones and tiered double-digit royalty payments.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription